The anticentromere antibody (ACA) test is primarily ordered to help diagnose the autoimmune disorder limited cutaneous scleroderma, a form of systemic scleroderma, and CREST syndrome. The test may be used to distinguish between this and other conditions with similar symptoms.
It may be ordered along with a Scl-70 (anti-topoisomerase) test, usually performed as part of an ENA panel (Extractable Nuclear Antigen antibody panel). Scl-70 is another autoantibody that may be present with scleroderma.
An ACA test may be ordered along with other tests for autoantibodies, including ANA.
If a person is positive for ACA and has symptoms of CREST, then it is likely that the person has limited cutaneous scleroderma. ACA is found in about 60-80% of people who have limited cutaneous scleroderma and can be present in up to 95% of those who have CREST syndrome.
If someone is negative for ACA, then it is likely that the person's symptoms are due to another condition. However, it is possible, though rare, that the individual has limited cutaneous scleroderma and does not produce anticentromere antibodies.
Typically, only people who have CREST symptoms are tested for ACA. However, some people may be positive for ACA prior to the development of these symptoms and ACA may be performed in conjunction with testing for other autoimmune disorders.
The amount of ACA present does not, in general, correlate to the severity of a person's symptoms.
This article was last reviewed on January 29, 2016. | This article was last modified on January 29, 2016.
The review date indicates when the article was last reviewed from beginning to end to ensure that it reflects the most current science. A review may not require any modifications to the article, so the two dates may not always agree.
The modified date indicates that one or more changes were made to the article. Such changes may or may not result from a full review of the article, so the two dates may not always agree.